ImmunoVaccine Technologies Inc. Completes Scale-Up of VacciMax to Commercially Relevant Scale

03-Dec-2007

ImmunoVaccine Technologies Inc. (IVT) announced that it has successfully scaled-up the manufacturing process for its vaccine platform, Vaccimax(R). This work validates the suitability of the platform for commercial applications in therapeutic cancer and infectious disease indications. The manufacturing development was performed at Dalton Pharma Services, a Health Canada and GMP compliant pharmaceutical manufacturing and development company. The results show that IVT's vaccine delivery platform can be produced on a commercial scale.

IVT's product, VacciMax(R), is a vaccine-enhancement platform comprised of a special emulsion of liposomes, antigens, adjuvants and oil. To prepare VacciMax(R) for human cancer clinical trials, IVT has been developing its platform to meet all regulatory requirements including manufacturing in a GMP setting. The ability to scale-up, under GMP or good manufacturing practices, is mandatory for various worldwide regulatory authorities, such as the FDA. By successfully producing VacciMax(R) at a commercially relevant batch size, IVT plans to license its vaccine technology worldwide for the therapy and prevention of cancer and infectious diseases.

IVT's testing verified that development batches produced at Dalton at an increasing scale retained their expected biological activity. Analytical testing also showed that the various elements of the platform are chemically stable. The latest batch produced at the 50 litre scale also met manufacturing and chemical specifications.

https://www.bionity.com/en/news/75325/immunovaccine-technologies-inc-completes-scale-up-of-vaccimax-to-commercially-relevant-scale.html